Your Unread Messages
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
Management of acromegaly in Latin America: expert panel recommendations
Pituitary, 11/06/09
Barkan A et al. – Surgical resection remains the mainstay of therapy for small pituitary adenomas (microadenomas), potentially resectable macroadenomas and invasive adenomas causing visual defects. Radiotherapy may be indicated in selected cases when no disease control is achieved despite optimal surgical debulking and medical therapy. Since not all the diagnostic tools and treatment options are available in all Latin American countries, physicians need to adapt their clinical management decisions to the available local resources and therapeutic options.
Related Articles
The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 88%
The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 87%
Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity
Hormone and Metabolic Research, 10/06/09
Relevance Score: 87%
Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients
Clinical Endocrinology, 10/15/09
Relevance Score: 85%
ACTH Deficiency, Higher Doses of Hydrocortisone Replacement, and Radiotherapy Are Independent Predictors of Mortality in Patients with Acromegaly
Journal of Clinical Endocrinology and Metabolism, 10/14/09
Relevance Score: 85%
Today in Neuroendocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines
Neuroendocrinology, 11/24/09
Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
Journal of Clinical Endocrinology and Metabolism, 11/20/09
Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with GNAS Gene Mutation
Journal of Clinical Endocrinology and Metabolism, 11/20/09
Sponsor
Article Search
Sponsor


See All


